Showing 7181-7190 of 9550 results for "".
- Galderma's Restylane Refyne and Restylane Defyne Fillers FDA Approved for “Laugh Lines”https://practicaldermatology.com/news/galdermas-restylane-refyne-and-restylane-defyne-fillers-fda-approved-for-laugh-lines/2458349/The FDA approved two new products for the treatment of nasolabial folds (NLF) or “laugh lines,” in patients over the age of 21—Galderma's Restylane Refyne and Restylane Defyne. Restylane Refyne was approved for the treatment of moderate to severe facial wrinkl
- CDC Study: Banning Indoor Tanning Among Minors Will Save Lives, Moneyhttps://practicaldermatology.com/news/banning-indoor-tanning-among-minors-will-save-lives-money/2458354/An age restriction on indoor tanning could save thousands of lives and millions of dollars, according to new research published online in the Journal of the American Academy of Dermatology. In December 2015, the U.S. Food and Drug Administration
- 8th Annual CSF Meeting Kicks Offhttps://practicaldermatology.com/news/8th-annual-csf-meeting-kicks-off/2458356/The Cosmetic Surgery Forum (CSF), now in its eighth year, was founded by NE-based dermatologist Joel Schlessinger, MD. CSF is a three-day multi-specialty educational symposium that covers the latest research, treatment and techniques in dermatology and cosmetic surgery. Unlike other meetings, res
- Study: Anxiety Linked to Skin Diseasehttps://practicaldermatology.com/news/study-anxiety-linked-to-skin-disease/2458359/Anxiety disorders tend to be followed by skin diseases, according to psychologists at the University of Basel in Switzerland and Ruhr University Bochum in Germany. The study, which appears in the journa
- New Combo Therapy Beats Out Gold Standard Treatment For AKshttps://practicaldermatology.com/news/new-combo-therapy-beats-out-gold-standard-treatment-for-aks/2458360/Combining a cream formulation of 5-fluorouracil with a synthetic form of vitamin D called calcipotriol may trigger a robust immune response against actinic keratosis, according to research out of rom Washington University School of Medicine in St. Louis and Harvard Medical School in Boston.
- ADAM Accepting Nominations for Practice Manager of the Yearhttps://practicaldermatology.com/news/adam-accepting-nominations-for-practice-manager-of-the-year/2458363/The Association of Dermatology Administrators and Managers is accepting nominations for its annual Practice Manager of the Year Award. Now in its fourth year, the Practice Manager of the Year Award recognizes the office professional who best demonstrates innovative thinking, ins
- Office Job, Stress And Diet May Increase Risk of Adult Acnehttps://practicaldermatology.com/news/office-job-stress-diet-may-increase-risk-of-adult-acne/2458370/Lifestyle factors -- including stress -- may play a role in adult acne development, a new study suggests. Researchers in Italy compared 248 women diagnosed with adult acne to 270 women without acne. They found that adult acne was associated with a personal history of acne in adolesce
- New From Dr. Macrene 37 Actives: High Performance Anti-Aging and Filler Lip Treatmenthttps://practicaldermatology.com/news/new-from-dr-macrene-37-actives-high-performance-anti-aging-and-filler-lip-treatment/2458388/Dr. Macrene 37 Actives is rolling out a new needle-free anti-aging lip filler. 37 Actives High Performance Anti-Aging and Filler Lip Treatment is formulated with more than 20 anti-aging actives including high concentrations of hyaluronic acid and peptides to fight the appearance of wrinkl
- Allergan Completes Vitae Tender Offerhttps://practicaldermatology.com/news/allergan-completes-vitae-tender-offer/2458391/Allergan completed their tender offer to purchase all outstanding shares of Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company. A tender offer occurs when
- Biofrontera Launches Ameluz for Actinic Keratosishttps://practicaldermatology.com/news/biofrontera-launches-ameluz-for-actinic-keratosis/2458397/Biofrontera AG initiated the US commercial launch of its combination topical prescription drug Ameluz and medical device BF-RhodoLED, which has been FDA approved to treat mild to moderate actinic keratosis (AK) on the face and scalp. Ameluz is used in combination with the medical device B